Wayshine Biopharm, Inc.
3 clinical trials · Sponsor
◉ Watch Wayshine Biopharm, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (NCT07206498) | Wayshine Biopharm, Inc. | 2025-10-17 |
| A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer (NCT06868485) | Wayshine Biopharm, Inc. | 2025-08-18 |
| A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer (NCT06631989) | Wayshine Biopharm, Inc. | 2024-09-04 |
Track Wayshine Biopharm, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.